Latest Articles
Age, Race Play a Role in Endometrial Cancer Outcomes - Cancer Nursing Today
Age, Race Play a Role in Endometrial Cancer Outcomes Cancer Nursing Today
Published: Sept. 3, 2025, 11:02 p.m.
The molecular role of RE1 silencing transcription factor in uterine diseases: is there potential for targeted therapeutic development?
Published: Sept. 3, 2025, midnight
XPR1: Emerging Prognostic Marker in Endometrial Cancer - BIOENGINEER.ORG
XPR1: Emerging Prognostic Marker in Endometrial Cancer BIOENGINEER.ORG
Published: Sept. 2, 2025, 9:51 a.m.
Lactate-Induced M2 Macrophages Boost Endometrial Cancer Progression - BIOENGINEER.ORG
Lactate-Induced M2 Macrophages Boost Endometrial Cancer Progression BIOENGINEER.ORG
Published: Aug. 29, 2025, 10:40 p.m.
Research progress of probiotics intervention on reconstruction of intestinal flora and improvement of quality of life in patients after endometrial cancer surgery - Frontiers
Research progress of probiotics intervention on reconstruction of intestinal flora and improvement of quality of life in patients after endometrial cancer surgery Frontiers
Published: Aug. 29, 2025, 7:07 p.m.
Survival Varies by Age With HT in Endometrial Cancer - Medscape
Survival Varies by Age With HT in Endometrial Cancer Medscape
Published: Aug. 28, 2025, 3:05 p.m.
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. - AInvest
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. AInvest
Published: Aug. 28, 2025, 8:24 a.m.
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork
Published: Aug. 26, 2025, 10:07 p.m.
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value AInvest
Published: Aug. 26, 2025, 7:31 p.m.
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer - Targeted Oncology
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology
Published: Aug. 26, 2025, 6:30 p.m.
Link copied to clipboard!